Labetalol: Nursing Drug Guide, IV Hypotension & NCLEX Review

Oral labetalol is marketed as Trandate (labetalol hydrochloride tablets) and as generic labetalol tablets. IV labetalol is available as generic labetalol hydrochloride injection (multiple manufacturers including Hikma) and institution-specific pharmacy-prepared syringes or infusion bags.

Verify the MAR lists both generic and brand names—IV bolus errors often trace to mg/kg calculations or confusing labetalol bags with other antihypertensive syringes in the medication room.

Per IV and oral Trandate prescribing information, labetalol is used for hypertension—including severe hypertension requiring IV therapy when rapid blood-pressure reduction is needed—and for chronic oral blood-pressure control. It is commonly selected when combined alpha- and beta-blockade is desired without unopposed beta blockade alone.

On obstetric units, IV labetalol may be used for acute severe hypertension in pregnancy when prescriber and protocol support it; fetal heart rate monitoring and maternal perfusion checks remain essential because both alpha and beta pathways are blocked.

↔On a small screen, swipe or scroll sideways to see the full table.

Labetalol blocks alpha-1 adrenergic receptors (peripheral vasodilation) and nonselectively blocks beta-adrenergic receptors (reduced heart rate and contractility). Combined blockade lowers blood pressure through decreased peripheral resistance and cardiac output.

Unlike pure beta blockers, the alpha-blocking component may reduce the reflex tachycardia sometimes seen with vasodilators alone—but IV labetalol still causes bradycardia and hypotension, especially when boluses are repeated too soon or when patients stand before orthostatic stability is confirmed.

Individualize all IV doses to patient weight and response. Independent double-check mg/kg bolus calculations and cumulative bolus totals before every repeat dose.

IV severe hypertension (label — Hikma labetalol injection)

Oral hypertension (label — Trandate tablets)

↔On a small screen, swipe or scroll sideways to see the full table.

IV to oral transition: When supine diastolic blood pressure begins to rise after effective IV therapy, initiate oral labetalol per prescriber orders rather than continuing to stack IV boluses without reassessment.

Abrupt oral withdrawal: Trandate labeling warns that abrupt cessation can exacerbate angina and increase myocardial infarction risk—taper per prescriber rather than stopping suddenly.

Pretreatment checks

• Perform medication reconciliation—confirm no IV verapamil ordered or running; verify oral transition plan when IV therapy is active
• Confirm cardiac telemetry or continuous monitoring for IV bolus and infusion therapy
• Assess baseline heart rate, supine and standing blood pressure when safe, lung sounds, and perfusion; review history of heart failure
• Verify patient weight, bolus mg/kg calculation, cumulative IV dose toward 300 mg maximum, and independent double-check
• Screen for reactive airway disease—labetalol is contraindicated in patients with asthma or obstructive airway disease per labeling

Contraindications

• IV: Bronchial asthma; heart block greater than first degree; cardiogenic shock; IV verapamil in close proximity; hypersensitivity
• Oral: Bronchial asthma; overt cardiac failure; heart block greater than first degree; cardiogenic shock; severe bradycardia; hypersensitivity

Warnings (labeling)

• Orthostatic hypotension: Symptomatic postural hypotension occurred in 58% of IV patients—maximal effect within ~5 minutes per dose; keep supine until reassessed
• Bradycardia and hypotension: Hold repeat boluses when heart rate or blood pressure crosses prescriber thresholds or when dizziness develops
• Cardiac failure: Negative inotropy can worsen decompensation—monitor for pulmonary edema and poor perfusion
• Diabetes: May mask tachycardia from hypoglycemia—teach patients with type 2 diabetes to monitor glucose closely
• Hepatic impairment: Oral labeling notes reduced metabolism—use caution and monitor blood pressure more frequently

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

IV route: Administer bolus doses over 2 minutes per labeling—do not push faster than prescribed. Continuous infusion at 2 mg/min may follow when ordered. Use dedicated line or verify compatibility per pharmacy guidance for IV therapy standards.

• Independent double-check weight, mg/kg bolus dose, cumulative total toward 300 mg maximum, and line assignment
• Reassess supine heart rate and blood pressure before every repeat bolus—do not administer on schedule alone
• Keep patient supine during and for several minutes after IV bolus; assist with first void using bedpan or commode if orthostasis risk is high
• Label syringe or line clearly as labetalol; communicate cumulative dose and last vitals at handoff
• Do not co-administer IV verapamil in close proximity

Oral route: Tablets may be taken with or without food per Trandate labeling. Swallow whole; do not skip doses without prescriber guidance because abrupt withdrawal can worsen angina.

• Gradual reduction in systolic and diastolic blood pressure toward prescriber-defined targets without symptomatic hypotension
• Improvement in hypertension-related symptoms such as headache or visual disturbance when those symptoms drove the acute order
• Heart rate and blood pressure stable in supine position before any assisted standing trial
• Transition orders to oral labetalol when supine diastolic blood pressure begins to rise after effective IV control
• Reduced palpitations when tachycardia accompanied severe hypertension—without new bradycardia or perfusion symptoms

Escalate immediately for perfusion failure, high-grade block, or suspected drug interaction.

• Symptomatic bradycardia or heart rate below prescriber minimum with dizziness, syncope, or altered mental status—hold repeat bolus or infusion
• Supine hypotension with poor perfusion, oliguria, or cool clammy extremities after IV bolus
• Presyncope or syncope on standing—assume orthostatic collapse risk; keep flat and notify prescriber
• New or worsening chest pain, pulmonary edema, or crackles suggesting cardiac failure
• Second- or third-degree heart block on monitor—hold and notify immediately
• IV verapamil ordered or discovered on MAR while labetalol is active—stop and clarify before either continues
• Bronchospasm or wheeze in patient with reactive airways—notify prescriber immediately

↔On a small screen, swipe or scroll sideways to see the full table.

Overdose manifests as excessive alpha/beta blockade—profound hypotension (often posture-sensitive), bradycardia, and cardiac failure.

Management (labeling)

• IV overdose: Supportive care only—place patient supine with legs raised per IV labeling
• Oral overdose — bradycardia: Atropine or epinephrine per prescriber and protocol
• Oral overdose — severe beta-blocker toxicity: Glucagon 5–10 mg IV per Trandate labeling when bradycardia and hypotension persist
• Hypotension: IV fluids and vasopressors such as norepinephrine as indicated
• Hemodialysis removes less than 1% of labetalol—do not rely on dialysis for clearance

Antidote: No single reversal agent—support hemodynamics until stable while monitoring electrolytes on a basic metabolic panel when clinically indicated.

• Labetalol vs other IV antihypertensives—verify drug name, concentration, and line at bolus administration; do not confuse with similarly packaged syringes in emergency carts
• mg/kg vs flat mg dose—independent double-check every bolus; weight entry errors cause overdose
• Cumulative 300 mg bolus cap—track total IV bolus dose across shifts; clarify before exceeding label maximum
• Labetalol vs metoprolol orders—IV labetalol and oral metoprolol may appear during transition; clarify which is active and transition steps
• Repeat bolus q10min vs PRN response—do not treat interval as mandatory if patient is hypotensive or symptomatic
• Trandate vs Trandate HCT—confirm whether a diuretic combination is intended before administration

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Continuous ECG/telemetry during IV bolus therapy and until stable after transition to oral dosing
• Supine heart rate and blood pressure before, at 5 minutes, and at 10 minutes after each IV bolus per protocol
• Orthostatic blood pressure before first assisted standing when prescriber or protocol requires it
• Perfusion: mental status, urine output, skin temperature, and lung sounds
• Fetal heart rate in pregnancy when ordered alongside maternal hemodynamic checks
• Blood glucose in patients with diabetes when symptomatic

Document

• Indication, weight used for mg/kg calculation, bolus dose, cumulative IV total, and prescriber BP/HR targets
• Each bolus with paired vitals, orthostatic attempt results, and nurse initials on double-check
• Held or delayed repeat boluses with prescriber/pharmacist notification
• Oral labetalol transition doses and rationale when IV therapy stops

• This medicine lowers blood pressure quickly when given IV—the team will check your pulse and blood pressure often and may keep you lying flat for a while
• Report dizziness, faintness, nausea, headache, chest discomfort, or feeling like your heart is beating too slowly before trying to stand
• Ask for help the first time you get out of bed—many people feel dizzy when standing after IV doses
• When switching to oral pills, take them exactly as directed; do not stop suddenly because chest pain can worsen
• If you have diabetes, monitor blood sugar as instructed because this medicine can hide low-sugar warning signs
• Rise slowly from sitting or lying down at home—labetalol can cause dizziness when you change position

Do not start or continue and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for IV labetalol in pregnancy severe hypertension using a tabbed case (MAR, labs, vitals, and nursing notes), plus priority action, select-all-that-apply cues, trend interpretation, matrix urgency, and overdose documentation cloze items tied to orthostatic hypotension, bradycardia, bolus stacking, and verapamil interaction risk.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.